Last updated: July 31, 2026
Cytosar-U is the branded injectable formulation of cytarabine, an antimetabolite chemotherapy used mainly in acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), blast-phase chronic myeloid leukemia and meningeal leukemia. Its commercial position is mature and largely generic. Current clinical development is focused on cytarabine-containing treatment regimens, not on new clinical development of the Cytosar-U brand itself.
Cytarabine remains clinically important because it is a core component of intensive AML induction and consolidation therapy. The product has limited standalone commercial differentiation, no meaningful biologic exclusivity barrier and limited prospects for branded revenue growth. Its market outlook is supported by persistent AML treatment demand, but constrained by generic competition, hospital purchasing pressure and the availability of alternative cytarabine formulations.
What is Cytosar-U and how is it used?
Cytosar-U is an injectable formulation containing cytarabine, also known as cytosine arabinoside or Ara-C. It is administered intravenously, subcutaneously or intrathecally, depending on the treatment protocol and indication. Cytarabine inhibits DNA synthesis after intracellular conversion to active nucleotide metabolites.
The FDA labeling identifies the following uses:
| Use |
Clinical role |
| AML |
Induction and consolidation chemotherapy, commonly as part of “7+3” regimens |
| ALL |
Combination chemotherapy in selected treatment protocols |
| Blast phase of CML |
Salvage or combination treatment |
| Meningeal leukemia |
Intrathecal treatment in selected patients |
| High-dose chemotherapy |
Intensification and consolidation in AML and other hematologic malignancies |
The FDA label includes conventional-dose and high-dose treatment schedules. High-dose cytarabine is frequently referred to as HiDAC and is used in AML consolidation or salvage therapy. Dose selection depends on disease subtype, age, organ function, prior therapy and treatment intent (U.S. Food and Drug Administration [FDA], 2023).
Cytarabine is also used in pediatric and adult oncology protocols outside the specific branded product label. Treatment regimens are generally determined by institutional protocols, cooperative group guidance and contemporary AML classification.
What clinical trials currently involve cytarabine?
Clinical trials involving cytarabine remain active, but most evaluate combination regimens rather than Cytosar-U as a standalone product. The main areas of study are AML induction, relapse treatment, measurable residual disease, targeted combinations and lower-intensity therapy for older or medically unfit patients.
AML induction and consolidation trials
Cytarabine remains the backbone of intensive AML induction. The conventional 7+3 regimen combines continuous-infusion cytarabine for seven days with an anthracycline administered over three days. Trials frequently modify the anthracycline, add a targeted drug or substitute a newer formulation of cytarabine.
Examples of active development areas include:
| Development area |
Cytarabine role |
Commercial implication |
| FLT3-mutated AML |
Combined with cytarabine and anthracycline, often with a FLT3 inhibitor |
Maintains cytarabine demand while shifting value to targeted agents |
| CD33-positive AML |
Combined with cytarabine-based chemotherapy and antibody-drug conjugates |
Supports combination use but does not create material brand differentiation |
| IDH1- or IDH2-mutated AML |
Used with targeted inhibitors in selected intensive regimens |
Expands treatment segmentation |
| Older adults |
Combined with lower-intensity agents or evaluated against non-intensive regimens |
May reduce use of conventional intensive cytarabine |
| Relapsed or refractory AML |
Used in salvage regimens such as FLAG-based therapy |
Preserves demand in later-line treatment |
| Measurable residual disease |
Used in intensified consolidation or investigational combinations |
Supports use in biomarker-selected treatment |
Clinical trials of newer cytarabine formulations
Some clinical development has focused on alternative delivery systems rather than the Cytosar-U formulation. The most important example is CPX-351, a liposomal formulation containing cytarabine and daunorubicin in a fixed combination. CPX-351 is marketed as Vyxeos and is approved for therapy-related AML and AML with myelodysplasia-related changes in certain adult and pediatric populations.
Vyxeos is not a generic substitute for every Cytosar-U use. Its clinical and regulatory positioning is narrower, and its formulation is protected by product-specific intellectual property and regulatory exclusivity. It competes for selected AML patients who might otherwise receive conventional cytarabine-based induction, particularly in high-risk disease (FDA, 2021).
ClinicalTrials.gov lists numerous studies involving cytarabine, but trial records often identify the active ingredient rather than the commercial brand. This distinction matters: a trial using “cytarabine” does not necessarily create additional commercial protection for Cytosar-U or indicate that Pfizer is sponsoring the study (National Library of Medicine, 2024).
What is the FDA regulatory status of Cytosar-U?
Cytosar-U is an established FDA-approved cytarabine injection product. The current prescribing information covers injectable administration and includes warnings relating to myelosuppression, gastrointestinal toxicity, neurotoxicity, ocular toxicity, pulmonary toxicity and tumor lysis syndrome.
Key regulatory characteristics include:
| Regulatory factor |
Status |
| Active ingredient |
Cytarabine |
| Dosage form |
Injectable solution or powder for reconstitution, depending on presentation |
| Main therapeutic area |
Hematologic malignancies |
| FDA pathway |
Legacy new drug application and subsequent generic cytarabine products |
| Biologic |
No |
| Biosimilar pathway |
Not applicable |
| Main regulatory competitors |
Generic cytarabine injections and alternative cytarabine-containing products |
| Primary buyers |
Hospitals, oncology centers, group purchasing organizations and specialty distributors |
Cytarabine is not a biologic, so biosimilar competition does not apply. Competitive pressure comes from abbreviated new drug application products, hospital contracts and alternative branded formulations.
What is the Orange Book status of Cytosar-U?
Cytosar-U does not have the commercial profile of a recently approved branded drug with a substantial Orange Book patent estate. Cytarabine is an old small-molecule active ingredient, and multiple FDA-approved generic cytarabine injection products have been marketed.
The FDA Orange Book is relevant to listed drug patents and exclusivity, but Cytosar-U’s commercial risk is primarily generic substitution rather than a current patent challenge. The product’s original composition and clinical use are long past ordinary small-molecule patent terms. Current market access depends more on manufacturing, supply reliability, injectable-product quality systems and institutional procurement than on exclusivity rights.
Does Cytosar-U have active composition patents?
No commercially meaningful composition-of-matter exclusivity remains for cytarabine. The molecule was developed decades ago, and any original patent protection has expired.
Potentially relevant intellectual-property categories include:
- Manufacturing processes for cytarabine or intermediates
- Crystallization and purification methods
- Container-closure systems
- Stability improvements
- Premixed or ready-to-use presentations
- Liposomal or other drug-delivery systems
- Combination products containing cytarabine and a second active ingredient
These rights would generally protect a particular process, formulation or combination rather than the cytarabine molecule itself. They do not prevent generic manufacture of conventional cytarabine injection where applicable patents and regulatory requirements have been satisfied.
When does Cytosar-U lose exclusivity?
Cytosar-U has already lost the exclusivity associated with its original active ingredient and initial product approval. Cytarabine is a mature generic drug.
There is no remaining pathway for a conventional “loss of exclusivity” event comparable to a high-value branded therapy approaching its patent cliff. Generic competition is already established. The relevant commercial question is whether a specific manufacturer can retain supply contracts, maintain quality compliance and preserve market share.
| Exclusivity category |
Cytosar-U status |
| Active ingredient patent |
Expired |
| Original product patent |
Expired or commercially irrelevant |
| Orphan-drug exclusivity |
Not the basis of current Cytosar-U protection |
| Pediatric exclusivity |
Not a current commercial barrier |
| New chemical entity exclusivity |
Expired |
| Biosimilar exclusivity |
Not applicable |
| Generic competition |
Established |
How many patents cover Cytosar-U?
No current patent estate of material commercial scope is generally associated with the conventional Cytosar-U injection itself. The relevant intellectual-property landscape is fragmented across cytarabine manufacturing, injectable formulation technology and newer combination products.
What formulations are protected around cytarabine?
The strongest formulation-related protection is more likely to attach to differentiated products than to conventional Cytosar-U injection. Examples include:
| Product or technology |
Differentiation |
| Conventional cytarabine injection |
Generic injectable active ingredient |
| Liposomal cytarabine-daunorubicin |
Fixed-ratio delivery system, marketed as Vyxeos |
| Depot or sustained-release cytarabine |
Investigational or specialized delivery approaches |
| Intrathecal formulations |
Route-specific preparation and institutional handling |
| Ready-to-use presentations |
Potential protection through formulation, container or manufacturing claims |
Liposomal cytarabine products may have meaningful patent and regulatory protections that do not apply to Cytosar-U. A patent analysis must therefore distinguish claims directed to cytarabine itself from claims directed to a specific delivery system or combination.
Which companies compete with Cytosar-U?
Competition is divided between generic cytarabine suppliers and differentiated AML products.
Generic cytarabine competitors
Cytarabine injection is supplied by multiple generic manufacturers and pharmaceutical distributors. Market participation can change because injectable oncology products are vulnerable to shortages, facility inspections, raw-material constraints and manufacturing discontinuations.
The competitive factors are:
- Contract price and hospital formulary status
- Supply continuity
- FDA manufacturing compliance
- Vial sizes and concentration availability
- Cold-chain and distribution capability
- Ability to support national group purchasing contracts
Branded and differentiated competitors
Cytosar-U also competes indirectly with:
- Vyxeos, a liposomal daunorubicin/cytarabine product
- Azacitidine-based regimens
- Decitabine-based regimens
- Venetoclax combinations
- FLT3 inhibitors such as midostaurin and quizartinib
- IDH inhibitors such as ivosidenib and enasidenib
- Targeted antibody-drug conjugates and investigational AML therapies
These products do not uniformly replace cytarabine. Many are used with cytarabine, in patients unsuitable for intensive cytarabine therapy or in disease subsets defined by molecular abnormalities.
How does Cytosar-U compare with Vyxeos?
Vyxeos has greater product differentiation and a stronger commercial protection profile than conventional Cytosar-U. Cytosar-U is a flexible, low-cost generic cytarabine product. Vyxeos is a fixed-ratio liposomal combination with a narrower approved indication and higher acquisition cost.
| Attribute |
Cytosar-U |
Vyxeos |
| Active ingredients |
Cytarabine |
Cytarabine and daunorubicin |
| Delivery |
Conventional injection |
Liposomal injection |
| Primary use |
Broad cytarabine-based chemotherapy |
Selected high-risk AML populations |
| Generic substitution |
High |
Limited |
| Product differentiation |
Low |
High |
| Patent exposure |
Minimal for conventional product |
Product- and formulation-specific |
| Pricing power |
Low |
Higher |
| Clinical flexibility |
High |
More protocol-specific |
| Main commercial risk |
Generic pricing and supply |
Payer access, competition and patent expiry |
Cytosar-U retains an advantage in protocol flexibility and cost. Vyxeos has a stronger differentiation strategy but faces a narrower eligible population and higher treatment cost.
What is the market size and revenue exposure for Cytosar-U?
Standalone global revenue for Cytosar-U is not generally disclosed separately by the manufacturer. Cytarabine revenues are often aggregated with broader hospital injectable or oncology portfolios. Public company reporting therefore does not provide a reliable product-level revenue series for the brand.
The economic value of cytarabine is better measured through treatment volume and regimen importance than through branded sales. It is used in a high number of AML treatment cycles, but the per-unit price of conventional cytarabine is low compared with targeted AML agents.
Market drivers
- Continued AML incidence and treatment demand
- Use in intensive induction and consolidation
- Use in salvage regimens
- Pediatric leukemia protocols
- Hospital preference for established generic products
- Periodic injectable-drug shortages that can shift market share
Market constraints
- Generic price competition
- Limited brand differentiation
- Declining use of intensive chemotherapy in frail or elderly patients
- Growth of venetoclax-based lower-intensity regimens
- Use of targeted therapies in molecularly defined AML
- Hospital purchasing consolidation
- Manufacturing and supply-chain disruptions
What is the Cytosar-U market projection?
Cytosar-U is likely to remain a stable, low-growth or declining branded product, while the broader cytarabine market should remain clinically durable. A reasonable commercial projection is:
| Period |
Expected market direction |
Primary drivers |
| 2024-2026 |
Stable demand with pricing pressure |
AML treatment volume, generic competition |
| 2027-2029 |
Low growth in unit demand, continued brand erosion |
Aging population offset by lower-intensity AML therapy |
| 2030 onward |
Durable clinical use but limited branded expansion |
Cytarabine remains embedded in intensive protocols |
The strongest demand will remain in AML induction, consolidation and salvage therapy. The largest erosion risk is substitution of intensive cytarabine-based regimens with venetoclax combinations and other lower-intensity approaches for older or medically unfit patients.
The broader cytarabine market should not be treated as a proxy for Cytosar-U revenue. Active ingredient demand can remain stable while the branded product loses share to generic suppliers or alternative formulations.
What generic entry risks exist for Cytosar-U?
Generic entry is already a structural feature of the market. The principal risks are not future Paragraph IV launches but ongoing substitution and supplier competition.
Paragraph IV challenges
Paragraph IV litigation is generally associated with a generic applicant challenging an unexpired patent listed for an approved branded product. For conventional cytarabine injection, the molecule and original product rights are old, and the commercial significance of a new Paragraph IV event is limited.
Potential Paragraph IV exposure could arise for:
- A newer cytarabine formulation
- A fixed-dose combination
- A delivery technology
- A ready-to-use product with formulation claims
- A product supported by method-of-use patents
Those challenges would concern the specific protected product, not necessarily Cytosar-U.
Generic launch scenarios
| Scenario |
Probability profile |
Impact |
| Additional generic supplier enters |
Routine market event |
Further price and share pressure |
| Existing supplier exits |
Possible in injectable markets |
Temporary shortages and price increases |
| Manufacturing warning or recall |
Episodic |
Short-term supply disruption |
| New differentiated cytarabine product |
Selective |
Could shift high-value patients from conventional injection |
| Lower-intensity AML adoption |
Gradual |
Reduces intensive cytarabine volume in some populations |
What manufacturing and intellectual-property barriers affect Cytosar-U?
The main barriers are operational rather than patent-based. Sterile injectable production requires validated aseptic processing, container-closure integrity, stability data, quality-control testing and compliance with current good manufacturing practice requirements.
Important barriers include:
- Sterile manufacturing capacity
- Cytotoxic handling controls
- Reliable active pharmaceutical ingredient supply
- Vial and packaging availability
- Batch-release testing
- Facility inspection history
- Hospital qualification and supplier contracts
- Ability to maintain supply during demand surges
These barriers can protect incumbent suppliers temporarily even when patent protection is absent. They do not create durable exclusivity comparable to a valid composition or formulation patent.
What patent litigation and settlement agreements affect Cytosar-U?
There is no major current patent-litigation narrative comparable to heavily litigated modern oncology brands. Conventional Cytosar-U is a mature product with limited patent leverage.
Litigation risk is more relevant to newer cytarabine-related products, particularly liposomal combinations, reformulated products and targeted combination regimens. Settlement agreements involving those products may include launch dates, licensing terms, authorized generic provisions or restrictions tied to specific patent claims. Such agreements should not be assumed to affect the conventional Cytosar-U market.
How strong is the Cytosar-U patent estate?
The patent estate for conventional Cytosar-U is weak from a present-day exclusivity perspective. Its commercial resilience comes from clinical entrenchment and protocol inclusion, not from patent protection.
| Estate component |
Assessment |
| Composition of matter |
Exhausted |
| Conventional injectable formulation |
Limited current protection |
| Method of use |
Broad uses are old and difficult to enforce as exclusivity |
| Manufacturing process |
Potentially relevant to individual suppliers |
| Delivery technology |
Stronger for differentiated products |
| Combination products |
Potentially meaningful for newer therapies |
| Geographic coverage |
Varies by product and jurisdiction |
| Overall brand protection |
Low |
What is the geographic coverage of Cytosar-U?
Cytarabine is used internationally in leukemia treatment, but the Cytosar-U brand may not be marketed under the same name or by the same company in every jurisdiction. Generic cytarabine injections are widely available through national and regional suppliers.
Geographic commercial performance depends on:
- National tender systems
- Hospital procurement rules
- Local generic approvals
- Oncology treatment guidelines
- Import requirements
- Sterile manufacturing capacity
- Reimbursement and pricing controls
Patent expiry is not the main geographic variable. Regulatory approval, supply continuity and tender participation determine access in most markets.
Key Takeaways
- Cytosar-U is the established injectable brand of cytarabine.
- Cytarabine remains a core component of intensive AML treatment.
- Current trials primarily evaluate cytarabine-containing combinations, not the Cytosar-U brand.
- Biosimilar risk does not apply because cytarabine is a small molecule.
- Conventional Cytosar-U has no meaningful remaining composition-of-matter exclusivity.
- Generic competition is already established.
- Vyxeos provides a differentiated, liposomal cytarabine-based alternative for selected AML patients.
- Market demand should remain clinically durable, but branded revenue growth is limited.
- The largest commercial risks are generic pricing, lower-intensity AML regimens and supply-chain disruption.
- Manufacturing quality, sterile capacity and hospital contracts are more important than patent protection for current Cytosar-U competitiveness.
FAQs
Is Cytosar-U still used for AML induction?
Yes. Cytarabine remains a central component of intensive AML induction, commonly in combination with an anthracycline and, where appropriate, a molecularly targeted agent.
Is Cytosar-U interchangeable with Vyxeos?
No. Vyxeos is a liposomal fixed-ratio combination of cytarabine and daunorubicin with different dosing, administration and approved-use parameters. It should not be treated as a simple generic substitute for Cytosar-U.
Does Cytosar-U have biosimilar competition?
No. Biosimilars apply to biological products. Cytosar-U contains the small-molecule drug cytarabine, so competition comes from generic injectable products.
Is cytarabine demand declining because of venetoclax?
Venetoclax-based regimens have reduced the need for intensive cytarabine-containing therapy in some older or medically unfit AML patients. Cytarabine remains important in intensive induction, consolidation, pediatric protocols and salvage therapy.
What is the main investment risk for Cytosar-U?
The main risk is commoditization. Price erosion, generic substitution and hospital procurement pressure are more material than patent expiration. Supply interruptions can temporarily improve pricing but do not create durable product value.
References
-
U.S. Food and Drug Administration. (2023). Cytosar-U (cytarabine) injection prescribing information. Pfizer Laboratories.
-
U.S. Food and Drug Administration. (2021). Vyxeos (daunorubicin and cytarabine) liposome for injection prescribing information. Jazz Pharmaceuticals.
-
National Library of Medicine. (2024). ClinicalTrials.gov database. U.S. National Library of Medicine.
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. Center for Drug Evaluation and Research.
-
Döhner, H., Wei, A. H., Appelbaum, F. R., Craddock, C., DiNardo, C. D., Dombret, H., Ebert, B. L., Fenaux, P., Godley, L. A., Hasserjian, R. P., Larson, R. A., Levine, R. L., Naoe, T., Nederlof, P. M., Niemeyer, C. M., Ossenkoppele, G. J., Sanz, M. A., Sierra, J., Tallman, M. S., Tien, H. F., ... Bloomfield, C. D. (2022). Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood, 140(12), 1345-1377.
